Cambridge (NASDAQ:CATC) reported quarterly earnings of $1.92 per share which missed the analyst consensus estimate of $2.05 by 6.34 percent. This is unchanged from the same period last year.
Cyclacel Pharmaceuticals To Present New Clinical Data At 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential As A Precision Medicine For Cancer
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE
